Sarepta Exercises Option to Acquire Myonexus Therapeutics
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Sarepta Therapeutics (SRPT) PT Raised to $213 at Cowen
February 28, 2019 6:21 AM ESTCowen analyst Ritu Baral raised the price target on Sarepta Therapeutics (NASDAQ: SRPT) to $213.00 (from $178.00) while maintaining a Outperform rating.
Baral commented, "SRPT reported 4Q18 with pre-announced Exondys revenues only slightly below consensus but meeting FY18 guidance. SRPT provided timeline updates for its... More
Sarepta (SRPT) Phase I/IIa MYO-101 Trial Data 'Striking' - SunTrust
February 27, 2019 11:55 AM ESTSunTrust analyst Edward Nash reiterated a Buy rating and $176 price target on Sarepta Therapeutics (NASDAQ: SRPT) following 'striking' preliminary results from a Phase I/IIa MYO-101 study in Limb-Girdle Muscular Dystrophy Type 2E (LGMD2E) or beta-sarcoglycanopathy, a severe and debilitating form of LGMD characterized by progressive muscle fiber loss,... More
Sarepta Therapeutics (SRPT) Hits Pre-market High, Up 7% with Conference Call Onoing
February 27, 2019 8:16 AM ESTSarepta Therapeutics (NASDAQ: SRPT) Hits Pre-market High, Up 7% with Conference Call Onoing
